References
- Jasperson KW, Tuohy TM, Neklason DW, et al. Hereditary and familial colon cancer. Gastroenterology 2010;138:2044-58
- Collins V, Halliday J, Warren R, et al. Assessment of education and counselling offered by a familial colorectal cancer clinic. Clin Genet 2000;57:48-55
- Balmana J, Balaguer F, Cervantes A, et al. Familial risk-colorectal cancer: ESMO clinical practice guidelines. Ann Oncol 2013;24(Suppl 6):vi73-80
- Giardiello FM, Allen JI, Axilbund JE, et al. Guidelines on genetic evaluation and management of Lynch syndrome: a consensus statement by the US multi-society task force on colorectal cancer. Dis Colon Rectum 2014;57:1025-48
- Stoffel EM, Kastrinos F. Familial colorectal cancer, beyond Lynch syndrome. Clin Gastroenterol Hepatol 2014;12:1059-68
- eviQ Cancer Treatments Online 2014. Cancer Institute NSW. Access date: 10 October 2014. Available from: https://www.eviq.org.au
- Qumseya BJ, Wallace MB. Advanced colorectal polyp detection techniques. Curr Gastroenterol Rep 2012;14:414-20
- Sehgal R, Sheahan K, O’Connell PR, et al. Lynch syndrome: an updated review. Genes 2014;5:497-507
- Kravochuck SE, Kalady MF, Burke CA, et al. Defining HNPCC and Lynch syndrome: what’s in a name? Gut 2014;63:1525-6
- Munoz J. Hereditary colorectal cancer follow-up. Available from: http://emedicine.medscape.com/article/188613-followup#a2650 [Last accessed on 13 June 2014]
- Kheirelseid E, Miller N, Kerin M. Molecular biology of colorectal cancer: review of the literature. Am J Molec Biol 2013;3:72-80
- Vasen HF, Watson P, Mecklin JP, et al. New clinical criteria for hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome) proposed by the International Collaborative group on HNPCC. Gastroenterology 1999;116:1453-6
- Australia CC. Bowel cancer: from prevention to palliation. Cancer Forum 2014;38
- Kidambi TD, Blanco A, Myers M, et al. Selective versus universal screening for lynch syndrome: a six-year clinical experience. Dig Dis Sci 2014. [Epub ahead of print]
- Mange S, Bellcross C, Cragun D, et al. Creation of a network to promote universal screening for lynch syndrome: the lynch syndrome screening network. J Genet Couns 2014. [Epub ahead of print]
- Toon CW, Walsh MD, Chou A, et al. BRAFV600E immunohistochemistry facilitates universal screening of colorectal cancers for Lynch syndrome. Am J Surg Pathol 2013;37:1592-602
- Ngeow J, Eng C. Population-based universal screening for Lynch syndrome: ready, set... How? J Clin Oncol 2013;31:2527-9
- Hill AL, Sumra KK, Russell MM, et al. A single institution experience in compliance with universal screening for lynch syndrome in colorectal cancer. J Gastrointest Surg 2015;19:543-50
- Heneghan HM, Martin ST, Winter DC. Segmental versus extended colectomy in the management of HNPCC; a systematic review and meta-analysis. Colorectal Dis 2014. [Epub ahead of print]
- Kalady MF. Surgical management of hereditary nonpolyposis colorectal cancer. Adv Surg 2011;45:265-74
- Natarajan N, Watson P, Silva-Lopez E, et al. Comparison of extended colectomy and limited resection in patients with Lynch syndrome. Dis Colon Rectum 2010;53:77-82
- Parry S, Win AK, Parry B, et al. Metachronous colorectal cancer risk for mismatch repair gene mutation carriers: the advantage of more extensive colon surgery. Gut 2011;60:950-7
- Haanstra JF, de Vos Tot Nederveen Cappel WH, Gopie JP, et al. Quality of life after surgery for colon cancer in patients with Lynch syndrome: partial versus subtotal colectomy. Dis Colon Rectum 2012;55:653-9
- Burn J, Mathers J, Bishop DT. Lynch syndrome: history, causes, diagnosis, treatment and prevention (CAPP2 trial). Digestive diseases 2012;30(Suppl 2):39-47
- Mathers JC, Movahedi M, Macrae F, et al. Long-term effect of resistant starch on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial. Lancet Oncol 2012;13:1242-9
- Thorson AG, Faria J. Familial adenomatous polyposis, hereditary nonpolyposis colon cancer, and familial risk: what are the implications for the surgeon? Surg Oncol Clin N Am 2000;9:683-97. discussion 99-701
- Omundsen M, Lam FF. The other colonic polyposis syndromes. ANZ J Surg 2012;82:675-81
- Vasen HF, Moslein G, Alonso A, et al. Guidelines for the clinical management of familial adenomatous polyposis (FAP). Gut 2008;57:704-13
- Latchford AR, Phillips RK. Duodenal adenoma and cancer in FAP. Gut 2005;54:171
- Koornstra JJ, Rijcken FE, Oldenhuis CN, et al. Sulindac inhibits beta-catenin expression in normal-appearing colon of hereditary nonpolyposis colorectal cancer and familial adenomatous polyposis patients. Cancer Epidemiol Biomarkers Prev 2005;14:1608-12
- West NJ, Clark SK, Phillips RK, et al. Eicosapentaenoic acid reduces rectal polyp number and size in familial adenomatous polyposis. Gut 2010;59:918-25
- Chow E, Lipton L, Lynch E, et al. Hyperplastic polyposis syndrome: phenotypic presentations and the role of MBD4 and MYH. Gastroenterology 2006;131:30-9